Updated Jul 16, 2026
Madaus Martin D has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $403K.
Martin D. Madaus is an experienced executive known for his roles in the biotechnology and life sciences sectors. He has served as a director for multiple companies, including Azenta, Inc. and Hologic, Inc., contributing to their strategic direction and governance.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-18 | RGEN | REPLIGEN CORP | A — Grant or award | 995 | $0.00 | |
| 2026-04-09 | HOLX | HOLOGIC INC | D — Derivative transaction | 5.4K | — | |
| 2026-04-09 | HOLX | HOLOGIC INC | D — Derivative transaction | 5.4K | — | |
| 2026-03-02 | HOLX | HOLOGIC INC | A — Grant or award | 3.2K | — | |
| 2025-08-08 | RGEN | REPLIGEN CORP | P — Open-market purchase | 1.8K | $112.13 | $202K |
| 2024-12-11 | HOLX | HOLOGIC INC | A — Grant or award | 342 | — | |
| 2024-11-19 | AZTA | Azenta, Inc. | P — Open-market purchase | 4.9K | $40.77 | $201K |
Martin D. Madaus is an experienced executive known for his roles in the biotechnology and life sciences sectors. He has served as a director for multiple companies, including Azenta, Inc. and Hologic, Inc., contributing to their strategic direction and governance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 2 open-market purchases ($403K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Madaus Martin D profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.